Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Level 1 - systematic review of randomized trials
Individual participant data meta-analysis of 23 large, double-blind randomized trials
PubMed 36049498 · doi:10.1016/S0140-6736(22)01545-8
What was done
An individual participant data meta-analysis evaluated adverse muscle events across large-scale double-blind randomized trials of statin therapy (recruiting ≥1,000 participants with scheduled duration ≥2 years). The dataset comprised 19 placebo-controlled trials (n=123,940) and 4 trials comparing higher-intensity versus lower-intensity statin regimens (n=30,724), analyzed using standard inverse-variance-weighted meta-analyses over a weighted average median follow-up of 4.3 years.
What was found
In placebo-controlled trials, 27.1% (16,835) of participants allocated statins versus 26.6% (16,446) on placebo reported muscle pain or weakness (rate ratio [RR] 1.03; 95% CI 1.01-1.06). In year 1, statin therapy caused a 7% relative increase in muscle complaints (RR 1.07; 95% CI 1.04-1.10), representing an absolute excess of 11 (95% CI 6-16) events per 1,000 person-years (~1 in 15 reports attributable to the drug). After year 1, there was no significant excess in first reports (RR 0.99; 95% CI 0.96-1.02). Across all years, intensive regimens had a higher RR versus placebo than less intensive regimens (1.08 [1.04-1.13] vs 1.03 [1.00-1.05]). Statins produced a clinically insignificant median creatine kinase increase of ~0.02 times the upper limit of normal.
Why it matters
These findings show that true statin-attributable muscle pain is rare and mainly confined to the first year of therapy, meaning >90% of muscle symptoms reported during statin treatment are not caused by the medication.
Limits
The study included only large trials (≥1,000 participants, ≥2 years duration), potentially excluding short-term or smaller trial data. Women comprised only 27.9% of participants in the placebo-controlled trials. The abstract does not detail specific anatomic symptom distributions or qualitative descriptions of pain beyond standard clinical adverse-event reporting.
Cited by
- context Statins cause severe leg cramps and muscle-related symptoms in patients.
- contradicts Approximately 20% of statin users experience muscle damage, muscle symptoms, or an increased risk of diabetes.